Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2011 1
2013 1
2014 1
2015 2
2016 2
2017 2
2018 2
2019 1
2020 4
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy for Multiple Myeloma.
Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Tamura H, et al. Among authors: ishibashi m. Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009. Cancers (Basel). 2019. PMID: 31842518 Free PMC article. Review.
Current and Future PET Imaging for Multiple Myeloma.
Ishibashi M, Takahashi M, Yamaya T, Imai Y. Ishibashi M, et al. Life (Basel). 2023 Aug 7;13(8):1701. doi: 10.3390/life13081701. Life (Basel). 2023. PMID: 37629558 Free PMC article. Review.
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. Tamura H, et al. Among authors: ishibashi m. Cancers (Basel). 2020 Apr 10;12(4):924. doi: 10.3390/cancers12040924. Cancers (Basel). 2020. PMID: 32290052 Free PMC article. Review.
Clinicopathologic Characteristics and A20 Mutation in Primary Thyroid Lymphoma.
Kuribayashi-Hamada Y, Ishibashi M, Tatsuguchi A, Asayama T, Takada-Okuyama N, Onodera-Kondo A, Moriya K, Igarashi T, Onose H, Tanosaki S, Yokose N, Yamaguchi H, Tamura H. Kuribayashi-Hamada Y, et al. Among authors: ishibashi m. J Nippon Med Sch. 2022 Jun 28;89(3):301-308. doi: 10.1272/jnms.JNMS.2022_89-305. Epub 2021 Nov 26. J Nippon Med Sch. 2022. PMID: 34840214 Free article.
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Ishibashi M, et al. Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410677 Free PMC article.
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. Ishibashi M, et al. Mol Cancer Res. 2020 Apr;18(4):632-643. doi: 10.1158/1541-7786.MCR-19-0391. Epub 2020 Jan 23. Mol Cancer Res. 2020. PMID: 31974290
23 results